Skip to main navigation Skip to search Skip to main content

COX2-dependent suppression of anticancer immunity

  • Cornell University

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Prostaglandin E2 (PGE2) is well known to promote tumor progression by boosting cancer cell proliferation while inhibiting anticancer immunity. Recent data from Lacher et al. and Morotti et al. demonstrate that one of the mechanisms through which PGE2 suppresses tumor-targeting immune responses involves downregulation of interleukin 2 (IL2) receptors and consequent inhibition of mitochondrial metabolism in T cells.

Original languageEnglish
Pages (from-to)573-575
Number of pages3
JournalTrends in Cancer
Volume10
Issue number7
DOIs
StatePublished - Jul 2024
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • apoptosis
  • CASP3
  • NK cells
  • PTGER2
  • radiation therapy
  • tumor-infiltrating lymphocyte
  • Receptors, Interleukin-2/metabolism
  • Cyclooxygenase 2/metabolism
  • Mitochondria/metabolism
  • T-Lymphocytes/immunology
  • Humans
  • Animals
  • Neoplasms/immunology
  • Dinoprostone/metabolism

Fingerprint

Dive into the research topics of 'COX2-dependent suppression of anticancer immunity'. Together they form a unique fingerprint.

Cite this